NephroDI Therapeutics

NephroDI Therapeutics, founded in 2017 by Jeff M. Sands, Janet D. Klein, Ish Khanna, and Ram Pillarisetti, is a biopharmaceutical company headquartered in Philadelphia, Pennsylvania. The company's core mission is to address kidney concentration disorders, with a particular focus on nephrogenic diabetes insipidus (NDI), a rare genetic condition affecting children. NephroDI aims to develop first-in-class treatments for these disorders, leveraging cutting-edge research and strategic collaborations to bring innovative therapies to market.

Notable affiliated individuals include co-founder Jeff M. Sands, who serves as the Chief Medical Officer. The company has entered into significant agreements, such as its collaboration with The McQuade Center for Strategic Research and Development, LLC (MSRD), and Otsuka, to advance the development of treatments for NDI. These partnerships highlight NephroDI's commitment to pioneering solutions in the biopharmaceutical landscape, positioning it as a key player in the field of kidney disorder therapeutics.